Joan Bladé, MD, from Hospital Clinic, Barcelona, Spain, gives an overview of when we should be treating patients who relapse. Currently, physicians wait until they see presentation of relapse symptoms, however, he recommends that, in fact, we should consider treatment when there is a significant paraproteinemic relapse. In this video, Prof. Bladé talks about a study that his group undertook, where they investigated this strategy and found something else interesting – that there is a sub-group of patients who may perform better without treatment after relapse. Although, how do we identify these patients? And how should we follow-up after treatment (or lack of)?
Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria.
This program was sponsored by Celgene through an unrestricted educational grant to Video Journal of Hematological Oncology.